Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Yuki KatayamaTadaaki YamadaRyo SawadaHayato KawachiKenji MorimotoSatoshi WatanabeKageaki WatanabeTakayuki TakedaYusuke ChiharaShinsuke ShiotsuMakoto HibinoTaishi HaradaNaoya NishiokaMasahiro IwasakuShinsaku TokudaKoichi TakayamaPublished in: The oncologist (2024)
Our results showed that RAM plus DOC after combined chemoimmunotherapy might be an effective and relatively feasible second-line treatment for patients with advanced NSCLC in a real-world setting.